Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

MoFlo Astrios EQ, a six-way jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter. The instrument sets a new standard for flow cytometry core facilities, delivering high-speed cell sorting and micro-particle detection in a single package. Featuring detailed and precise forward scatter resolution, beadless drop sample handling and increased biosafety, Astrios EQ meets a range of analysis needs.

2 May 2014

Variant of cell surface protein may help develop drugs for gastric cancer

A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

25 Apr 2014

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

New study by the Cancer Science Institute of Singapore and National University Hospital Singapore suggests that a variant of a cell surface protein is an ideal target for developing drugs to treat gastric cancer

23 Apr 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research, April 5-9, 2014 in San Diego, CA.

4 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results.

1 Apr 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Research shows depletion of cholesteryl ester impairs prostate cancer aggressiveness

Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods.

5 Mar 2014

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma.

31 Jan 2014

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

The Jackson Laboratory, in collaboration with Seoul National University, will receive a five-year, $7.5 million grant from the South Korean government for a large-scale cancer genomics project employing the latest sequencing technology and special JAX mouse models that can host human tumors.

22 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

New mutations in the estrogen receptor drive strong drug resistance exhibited by human breast tumors

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine in St. Louis.

13 Dec 2013

New book provides cutting-edge methods for generating and characterizing mouse cancer models

The laboratory mouse is an important model for addressing questions in cancer biology. In recent years, the questions have become more refined, and mouse models are increasingly being used to develop and test cancer therapeutics.

12 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

Xenograft News and Research

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

Variant of cell surface protein may help develop drugs for gastric cancer

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Research shows depletion of cholesteryl ester impairs prostate cancer aggressiveness

RNAi-based screening offers MPM treatment hope

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

New mutations in the estrogen receptor drive strong drug resistance exhibited by human breast tumors

New book provides cutting-edge methods for generating and characterizing mouse cancer models

New drug combination therapy effective for patients with HER2-positive breast cancer

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News